Enfusion (NYSE:ENFN) Announces Earnings Results

Enfusion (NYSE:ENFN) announced its quarterly earnings results on Monday. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02), Zacks reports. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The firm had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million.

Enfusion Stock Performance

NYSE ENFN opened at $11.39 on Wednesday. The stock has a market capitalization of $1.46 billion, a P/E ratio of 284.70, a P/E/G ratio of 1.85 and a beta of 0.96. The business’s fifty day moving average is $10.93 and its two-hundred day moving average is $9.83. Enfusion has a 1 year low of $7.83 and a 1 year high of $11.80.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ENFN shares. William Blair reissued a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Stifel Nicolaus upped their target price on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, Piper Sandler increased their price target on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $11.13.

Insider Transactions at Enfusion

In other Enfusion news, CFO Bradley Herring sold 24,443 shares of Enfusion stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $10.61, for a total transaction of $259,340.23. Following the transaction, the chief financial officer now directly owns 270,503 shares in the company, valued at approximately $2,870,036.83. The trade was a 8.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Oleg Movchan sold 2,771 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the transaction, the chief executive officer now owns 526,702 shares in the company, valued at approximately $5,335,491.26. This represents a 0.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,566 shares of company stock valued at $372,671 over the last three months. Company insiders own 36.44% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.